Turn this list into pipeline.
Precision Medicine Companies in London: 40+ Active Firms (2026)
Precision medicine companies in London develop genomic testing, biomarker analysis and data-led tools for more targeted healthcare.
Buying centres cluster around hospital-facing diagnostics, life-sciences R&D, specialist laboratory operations and clinical-data teams. Customers are usually healthcare providers, research organisations, pharmaceutical groups, diagnostics labs and medtech buyers, with some public-sector exposure where tools sit close to care pathways. Engagements tend to be evidence-heavy: assays, biomarker panels, bioinformatics platforms and decision-support workflows are bought through pilots, validation work and procurement rather than casual software trials. London’s buyer base also expects clinical credibility, information-governance discipline and the ability to work with laboratory or research-led operating models, so sales cycles often look more consultative than self-serve.
Read more
London has 42 actively trading precision medicine firms in this list, a narrow cohort by UK life-sciences standards and one that is better read at category level than as a broad software market. Reported headcount across the cohort totals 646 people, reflecting a mix of lean specialist teams and more established laboratory or clinical employers. A small subset sits above £5M turnover, while a similarly sized younger group has incorporated since 2022, leaving the market split between commercially proven operators and earlier-stage firms still building clinical evidence, partnerships and repeatable sales routes.
Precision medicine sits across clinical, laboratory and software obligations rather than a single licence boundary. Tests and biomarker services tend to encounter MHRA rules where a diagnostic product is placed on the market; clinical delivery brings quality and governance expectations; patient-level genomic and health information brings ICO and GDPR duties. Commercial buyers also care about evidence generation, sample handling, interoperability and whether tools can be used in clinical pathways, so procurement cycles are usually slower than for general life-sciences software.
The market appears to be moving away from discovery-led platforms that depend on long research partnerships and towards narrower clinical workflows where evidence, reimbursement and integration can be argued more plainly. Many London firms still look specialist rather than scaled, so buyers may see consolidation around laboratory capacity, clinical decision support and regulated analytics. Procurement tends to reward defensible validation over broad positioning. Regulatory pressure is unlikely to disappear; it may favour teams that can pair bioinformatics depth with clinical governance and commercial discipline.
42
Active firms
2026
7
Above £5M
reported revenue
7
Since 2022
newer incorporations
Key facts
About 16% of the trading cohort reports turnover above £5M (7 of 42 firms) — the rest sits below that revenue band.
16% of the cohort was incorporated since 2022 (7 firms), so a sizeable share is in its first few filing cycles.
London precision medicine firms work across genomic testing, biomarker analysis and data-led healthcare tools for more targeted diagnosis and treatment.
The segment sits between life sciences, diagnostics and software, so buyer conversations tend to centre on clinical evidence, patient stratification and analytics.
Specialist diagnostics, biomarker and health-data models make the market distinct from general healthtech.
Top London precision medicine companies
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsDevelops and supplies genomic analysis products including FISH probes, next‑generation sequencing panels and aCGH arrays, with associated software and kits used by clinical and research laboratories…
Sells to clinical and research laboratories, including cytogenetics, haematology, oncology and rare disease testing teams. Also serves precision medicine and biopharma partners running clinical trial…
Financial Health
DistressedDistressed · -45% CAGR over 1y
Location
Trajectory
4y · 2021–NowFinancial sub-scores
Computed from 4 filingsDevelops and commercialises blood-based multi‑cancer early detection tests, including the Galleri test, using next-generation sequencing and machine learning to identify cancer signals in DNA from…
Serves healthcare systems, clinicians and public health organisations, and reaches individuals through employer, life insurance and fire department screening programmes; also partners with biopharma…
Financial Health
StrongStrong · Hiring · 111% CAGR over 4y
Location
OWKIN UK LTD
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDevelops artificial intelligence software for biomedical research and healthcare. Provides AI tools for pharmaceutical drug discovery and development, analysis of patient and multi‑omics data, and…
Serves pharmaceutical R&D teams, clinical trial sponsors, clinicians and pathology labs in oncology, plus healthcare data partners and research organisations using AI-driven drug discovery and…
Financial Health
StrongStrong · Hiring · 65% CAGR over 2y
Location
Develops semiconductor-based DNA sequencing diagnostic systems for near‑patient testing. Its LiDia-SEQ platform performs direct-from-specimen genomic analysis to detect infectious diseases, including…
Targets hospital laboratories, clinicians and healthcare providers managing infectious disease, antimicrobial resistance and sepsis cases, with future relevance to oncology testing and monitoring.
Location
Trajectory
3y · 2022–NowDevelops bio‑crystallography diagnostic technology for early cancer detection. Uses X‑ray crystallography and machine learning to analyse extracellular matrix biomarkers from patient samples to…
Targets healthcare providers, breast imaging centres, oncology clinics and women’s health services caring for women at risk of breast cancer or undergoing cancer treatment.
Financial Health
Insufficient historyInsufficient history
Location
Metabolon
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsProvides metabolomics testing and analysis services for life sciences and biopharma research, including untargeted and targeted metabolite profiling, lipidomics and metagenomic sequencing, supported…
Serves biopharmaceutical companies, life sciences research teams, drug development groups, and microbiome or multiomics scientists involved in discovery, biomarker, pharmacokinetics, and biological…
Financial Health
StrongStrong · Hiring · 47% CAGR over 2y
Location
Trajectory
4y · 2023–NowFinancial sub-scores
Computed from 4 filingsDevelops a consent-based health data platform that links patients’ electronic health records, genomic data, biomarkers and reported outcomes. Provides pharmaceutical sponsors with real‑world evidence…
Serves life sciences sponsors, including pharmaceutical and biotech teams seeking consented patient cohorts and real-world evidence; also engages patients, healthcare professionals and investors.
Financial Health
StableStable · -13% CAGR over 3y
Location
SOPHIA GENETICS LIMITED
Trajectory
4y · 2020–NowFinancial sub-scores
Computed from 4 filingsDevelops cloud-based software that uses AI to analyse genomic and medical imaging data. Provides a platform for clinicians, laboratories and biopharma companies to interpret data, support diagnosis…
Serves healthcare providers and BioPharma companies, including oncologists, radiologists, pathologists, geneticists, lab technicians and bioinformaticians working in cancer, rare disease and…
Financial Health
HealthyHealthy · Hiring · 15% CAGR over 5y
Location
Health Services Laboratories
Provides clinical pathology and diagnostic laboratory services for healthcare providers, including biochemistry, microbiology, haematology, genetics, immunology and virology testing, cervical…
Serves NHS trusts, hospitals, clinicians and other healthcare providers, as well as researchers and clinical trial teams requiring specialist laboratory support.
Location
Develops semiconductor-based DNA sequencing technology and diagnostic platforms for rapid genomic analysis at the point of care. Builds microchip sequencing systems and tests for detecting infectious…
Targets hospitals, clinicians and clinical laboratories, especially teams managing infectious disease, sepsis and antimicrobial resistance, with relevance to healthcare systems and public health…
Location
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops and provides laboratory diagnostic assays and analytical services that assess tumour chemosensitivity and immune response markers to guide selection of chemotherapy, targeted therapies, and…
Serves healthcare providers and clinical teams treating patients with cancer and autoimmune diseases, including oncology practices, hospitals and translational medicine researchers.
Financial Health
StrongStrong · Hiring · 11% CAGR over 4y
Location
Mendelian Ltd
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDevelops software tools for healthcare providers to identify patients with potential rare diseases earlier. Its MendelScan platform analyses clinical data to flag undiagnosed cases, support case…
Serves healthcare providers, clinicians and primary care organisations, including NHS settings, involved in rare disease diagnosis, genomic testing decisions and specialist patient referrals.
Financial Health
WeakWeak · -7% CAGR over 2y
Location
Precious Md Ltd
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops AI‑based medical imaging software for lung cancer screening and diagnostics. Products include tools that analyse CT imaging data to detect early lung cancer, prioritise abnormal scans for…
Sells to healthcare organisations, including radiology departments, hospitals, diagnostic imaging providers and lung cancer screening programmes, with radiologists and oncology teams as key users.
Financial Health
StrongStrong · 0% CAGR over 2y
Location
Develops gene therapies for ophthalmic diseases, focusing on inherited and degenerative retinal disorders. Conducts research and clinical trials using AAV‑based gene therapy targeting conditions…
Serves patients and caregivers affected by inherited and age-related retinal diseases, alongside ophthalmology healthcare providers and clinical trial participants for XLRP, dry AMD and cone rod…
Location
Sano Genetics Ltd
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops a software platform for precision medicine and clinical research that supports patient recruitment, genetic and biomarker testing, electronic medical record retrieval, digital consent, and…
Serves life sciences sponsors, CROs, clinical trial sites, and research initiatives running precision medicine studies, including pharma/biotech teams and patient advocacy or population genomics…
Financial Health
StrongStrong · Hiring · 57% CAGR over 4y
Location
Swarm Oncology Limited
Trajectory
2y · 2023–NowFinancial sub-scores
Computed from 2 filingsDevelops personalised T cell therapies for cancer treatment. Uses a platform combining in vivo priming and ex vivo optimisation to create targeted cell therapies designed to recognise…
Serves oncology healthcare and life sciences organisations, including hospitals, research collaborators and commercial partners, with engagement also aimed at specialist investors in T cell therapy.
Financial Health
WeakWeak · Hiring · 100% CAGR over 1y
Location
Health Services Laboratories
Provides clinical pathology and diagnostic laboratory services for healthcare providers. Conducts medical testing across disciplines including biochemistry, genetics, microbiology, immunology,…
Serves NHS trusts, hospitals and healthcare providers requiring pathology and diagnostic testing, plus clinical researchers and trial teams needing laboratory expertise.
Location
PL Diagnostics Ltd
Trajectory
2y · 2023–NowFinancial sub-scores
Computed from 2 filingsDevelops and supplies point‑of‑care diagnostic devices and test kits for in‑vitro detection of biomarkers. Products include portable analysers and immunoassay-based testing systems using…
Serves healthcare providers and point-of-care testing centres, including clinics, pharmacies, nursing homes, health centres and other community or primary care settings.
Financial Health
DistressedDistressed · -17% CAGR over 1y
Location
Health Services Laboratories
Provides clinical pathology and diagnostic laboratory services including biochemistry, microbiology, genetics, immunology, haematology, virology and cervical screening. Processes medical samples and…
Serves NHS trusts and healthcare providers, including hospital clinicians and their patients, as well as research and clinical trial organisations requiring laboratory expertise.
Location
Trajectory
3y · 2022–NowFinancial sub-scores
Computed from 3 filingsDevelops, manufactures and distributes molecular-based diagnostic tests and animal genotyping kits. Provides diagnostic kits and establishes turnkey molecular, forensic and PGD laboratories, with…
Sells to B2B laboratory customers, particularly molecular diagnostic laboratories, forensic laboratories and PGD laboratories, as well as organisations needing animal genotyping and diagnostic test…
Financial Health
StableStable · 0% CAGR over 2y
Location
MY PERSONAL THERAPEUTICS LTD
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops genomics‑based clinical decision support and drug screening services for cancer treatment. Uses tumour exome sequencing and fruit fly disease models to test approved and investigational…
Serves cancer patients and their families, particularly those with complex or hard-to-treat colorectal, lung, pancreatic and other GI cancers, as well as oncologists seeking personalized treatment…
Financial Health
StableStable · 2% CAGR over 4y
Location
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops computational and machine learning software for oncology, analysing molecular and clinical data to predict patient response to cancer therapies. Provides a platform for visualising datasets,…
Serves biopharma and oncology research teams, plus clinical research users developing cancer therapies. Targets partners using molecular and clinical data for therapeutic development, translational…
Financial Health
StrongStrong · Growing, Hiring · 37% CAGR over 4y
Location
Health Services Laboratories
Provides clinical pathology and diagnostic laboratory services for healthcare providers. Conducts medical testing across disciplines including biochemistry, haematology, microbiology, virology,…
Serves NHS trusts and their customers, including hospitals, clinicians and healthcare providers needing pathology and diagnostic testing. Also targets research and clinical trial organisations…
Location
Health Services Laboratories
Provides clinical pathology and diagnostic laboratory services for healthcare providers, including biochemistry, haematology, microbiology, immunology, genetics, virology and cellular pathology.…
Serves NHS trusts, hospitals and other healthcare providers, supporting clinicians and their patients, and also works with academic, pharmaceutical and clinical research organisations involved in…
Location
Aceso AI Ltd
Trajectory
4y · 2021–NowFinancial sub-scores
Computed from 4 filingsDevelops an artificial intelligence platform that analyses electronic health record data alongside patient genotype and phenotype information to help clinicians identify complex diseases, suggest…
Serves B2B healthcare customers, particularly GPs, specialists and other healthcare providers involved in complex disease diagnosis, as well as life sciences, pharmaceutical and government partners…
Financial Health
WeakWeak · Hiring · 24% CAGR over 3y
Location
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops and commercialises blood‑based diagnostic tests and research assays using nucleosome and epigenetic biomarkers. Products include Nu.Q assays for detection and monitoring of cancer, sepsis…
Sells to clinicians and healthcare laboratories, clinical and preclinical researchers, pharmaceutical drug-development teams and veterinary practices involved in human disease monitoring, epigenetics…
Financial Health
StrongStrong · Hiring · 21% CAGR over 4y
Location
THE GLOBAL PATHOGEN ANALYSIS SERVICE LIMITED
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsProvides genomic sequencing analysis platforms for infectious disease surveillance, analysing pathogen genomes to identify species, lineages, related isolates, and drug resistance in organisms…
Serves public health agencies, clinical and research laboratories, and healthcare organisations involved in infectious disease surveillance and genomic sequencing, particularly teams working on…
Financial Health
StableStable · -7% CAGR over 2y
Location
Koneksa Health
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops digital biomarker technologies and software for clinical trials, using connected devices and remote data collection to measure patient outcomes. Provides data engineering, analytics, and…
Serves pharmaceutical and biotech clinical trial sponsors, clinical operations teams and researchers developing therapies in neuroscience, including Parkinson’s, MS and rare disease programmes.
Financial Health
StrongStrong · Hiring · 48% CAGR over 5y
Location
CHAMPIONS ONCOLOGY UK LIMITED
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsProvides contract research services for oncology drug development, including preclinical studies using patient‑derived tumour models, in vivo and ex vivo testing platforms, and laboratory assays such…
Serves global pharmaceutical and biotech companies, particularly oncology R&D, translational science and clinical development teams working on cancer drug programmes.
Financial Health
DistressedDistressed
Location
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops non-invasive skin testing and epigenetic analysis using tape-strip sampling and next-generation sequencing to measure biological skin ageing, inflammation and UV damage, providing biomarker…
Serves pharmaceutical, aesthetics and skincare companies, including clinical trial and R&D teams developing dermatological therapeutics and skin longevity products.
Financial Health
StrongStrong · Hiring · 32% CAGR over 4y
Location
AXOVIA THERAPEUTICS LTD
Trajectory
3y · 2024–NowFinancial sub-scores
Computed from 3 filingsDevelops gene therapies for genetic ciliopathy disorders including Bardet-Biedl syndrome. Its lead programme uses AAV9 viral vectors to deliver functional BBS1 genes to tissues, aiming to treat…
Targets patients with ciliopathies, especially Bardet-Biedl Syndrome caused by BBS1 mutations, along with caregivers and specialist healthcare communities involved in genetic obesity and blindness.
Financial Health
HealthyHealthy · Hiring · 100% CAGR over 2y
Location
Develops gene therapies and delivery technologies targeting neurodegenerative disorders. Conducts research and clinical development of RNA‑silencing and other gene therapy treatments for conditions…
Serves patients and caregivers affected by neurodegenerative and retinal diseases, alongside clinical trial investigators and biopharma partners focused on FTD, ALS, Alzheimer’s/tauopathies and…
Location
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsDevelops cancer immunotherapy drugs for solid tumours. Uses tumour immunology research and screening platforms to identify immune‑evasion targets and build a pipeline of biomarker‑guided therapies,…
Serves the oncology therapeutics market, targeting cancer patients with prevalent solid tumors and the clinicians, hospitals and health systems involved in cancer care; also addresses biotech…
Financial Health
StableStable · 0% CAGR over 1y
Location
Trajectory
1y · 2024–NowConducts biotechnology research developing epigenetic partial‑reprogramming therapies for cancer and age‑related disease, investigates senolytic polyphenol compounds to remove senescent cells, and…
Targets life sciences investors, clinical research partners, and healthcare or diagnostics customers focused on cancer, ageing, longevity biomarkers, and healthspan interventions.
Financial Health
Insufficient historyInsufficient history
Location
Develops gene therapies for inherited and degenerative eye diseases. Conducts research and clinical trials using adeno-associated virus (AAV) gene therapy to treat conditions such as X‑linked…
Serves patients with inherited and age-related retinal diseases, plus healthcare providers and clinical trial partners involved in ophthalmic gene therapy for XLRP, dry AMD and cone rod dystrophy.
Location
Wave Science Limited
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDevelops RNA-based therapeutics using proprietary chemistry and RNA-targeting technologies. Conducts research, clinical development and manufacturing of medicines for genetic and metabolic disorders,…
Serves patients and families affected by serious rare and common disorders, plus healthcare, biopharma collaboration and investor stakeholders focused on RNA therapeutics.
Financial Health
HealthyHealthy · 0% CAGR over 2y
Location
SEQUOIA GENETICS LTD
Trajectory
2y · 2025–NowFinancial sub-scores
Computed from 2 filingsProvides research and analytical services using human genetic data, statistical genetics and Mendelian randomization to generate insights on disease biology and support drug target discovery and…
Serves pharmaceutical and biotech companies, life sciences investors and academic groups involved in drug discovery and development, particularly those using human genetic data to assess therapeutic…
Financial Health
StrongStrong · Growing, Hiring · 64% CAGR over 1y
Location
Micrographia Bio Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsConducts life sciences research developing AI‑driven spatial proteomics and microscopy technologies to visualise protein interactions inside cells, supporting drug discovery and the development of…
Financial Health
StrongStrong · Growing, Hiring · 28% CAGR over 4y
Location
NUNTIUS THERAPEUTICS LIMITED
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsDevelops mRNA-based genetic medicines using proprietary nanocarrier delivery systems, machine learning models, and nucleic acid engineering. Conducts drug discovery and development of therapies…
Targets pharmaceutical and biotech partners and, ultimately, patients with life-threatening diseases, particularly in cancer, lung disease and neurodegenerative disease treatment markets.
Financial Health
StableStable · Hiring · 40% CAGR over 3y
Location
Trajectory
3y · 2024–NowFinancial sub-scores
Computed from 3 filingsDevelops bacteriophage-based diagnostic technologies for detecting mycobacteria that cause tuberculosis in humans and animals. Produces the Actiphage blood test and related qPCR kits used for rapid…
Sells to B2B and healthcare/public-sector buyers needing mycobacterial diagnostics, including human TB screening programmes, clinical research teams, and animal health customers such as bovine TB,…
Financial Health
DistressedDistressed
Location
BIOCORTEX LTD
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsDevelops computational biology tools and knowledge graphs of human microbiome data to model interactions between bacteria, the immune system and drugs. Provides analytics platforms used by…
Sells to pharmaceutical and biotech companies involved in drug discovery and development, particularly teams working on therapeutics, clinical development and precision oncology where microbiome…
Financial Health
StrongStrong
Location
BIO MOLECULAR SYSTEMS LIMITED
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops and manufactures laboratory instruments and software for life science research and diagnostics, including real‑time PCR cyclers, automated liquid handling systems, and workflow software for…
Sells B2B to clinical diagnostics and life science research laboratories worldwide, including academic institutes, biotech and pharmaceutical teams running genomics, qPCR, NGS library prep and drug…
Financial Health
StrongStrong · Growing, Hiring · 19% CAGR over 4y
Location
Science Care Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsSupplies laboratory equipment and provides genomic testing services including whole genome sequencing, whole exome sequencing and targeted panels. Also offers bioanalytical and biopharmaceutical…
Serves B2B and healthcare customers involved in research, drug development and patient care, including laboratories, biopharmaceutical and bioanalytical organisations, and teams needing genomic…
Financial Health
StableStable · 0% CAGR over 4y
Location
Synteny Biotechnology Limited
Trajectory
5y · 2022–NowFinancial sub-scores
Computed from 5 filingsDevelops AI-driven computational platforms that analyse biological sequence, structure and physics data to model molecular recognition and design precision T‑cell receptor (TCR) bispecific therapies…
Serves biopharmaceutical companies and research organisations focused on immunology, oncology and biologic drug discovery, particularly teams seeking partners for precision TCR bispecific therapy…
Financial Health
WeakWeak · Hiring · 52% CAGR over 4y
Location
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsDevelops artificial intelligence-driven drug discovery technologies for precision medicine, focusing on identifying and developing treatments for brain diseases and cancers through integrated…
Serves patients with underserved brain diseases, including brain cancer, with a stakeholder audience that includes precision medicine, life sciences and technology investors.
Financial Health
StrongStrong · Hiring · 176% CAGR over 3y
Location
Exogene Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops machine‑learning and generative AI tools to discover and engineer T‑cell receptors (TCRs) for cancer immunotherapies. Uses computational models to analyse TCR sequence space and identify…
Financial Health
StableStable · Hiring · 11% CAGR over 4y
Location
Serac Healthcare Limited
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops molecular imaging agents for medical diagnostics. Focuses on 99mTc‑maraciclatide, a nuclear imaging tracer being developed to detect endometriosis and assess inflammatory arthritis activity,…
Serves healthcare providers, imaging departments and clinicians treating patients with endometriosis and inflammatory arthritis, including hospitals and health systems focused on personalised…
Financial Health
StableStable · Hiring · 6% CAGR over 4y
Location
Trajectory
5y · 2020–NowDevelops cancer immunotherapies based on natural killer (NK) cells and small‑molecule compounds. Uses stem cell‑derived and engineered NK cells to create therapeutic candidates targeting…
Targets the oncology market, with future customers and stakeholders including healthcare providers, cancer patients with haematological or solid tumours, and life sciences investors.
Financial Health
Insufficient historyInsufficient history
Location
OFFSPRING ACADEMY LTD
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsServes children and young people needing paediatric healthcare, plus their families and caregivers; also addresses international patients, referring clinicians, researchers and health professionals…
Financial Health
WeakWeak · -16% CAGR over 4y
Location
Trajectory
4y · 2021–NowFinancial sub-scores
Computed from 4 filingsDevelops point‑of‑care molecular diagnostic technologies and laboratory products, including nucleic acid extraction kits and reagents using magnetic‑based systems. Supplies testing platforms and…
Serves human and animal health organisations, life sciences researchers and diagnostic laboratories seeking research-use molecular testing and nucleic acid extraction products, plus bespoke research…
Financial Health
StableStable · -36% CAGR over 4y
Location
Unlock all 42 leads
Showing 50 of 42 — +0 more with verified decision-maker contacts, live data, and CRM sync.
How London precision medicine companies work and how to sell to them
What they do
Revenue usually comes from a mix of test volumes, laboratory service fees, software licences, research collaborations and implementation work. Diagnostic-facing firms may price per assay, sample, report or clinical workflow, while data-led businesses more often charge annual licences, usage fees or project retainers for bioinformatics, analytics and decision-support. Specialist service providers tend to sell validation packages, managed laboratory capacity or contract research rather than pure software. Gross margins and cash timing can vary a great deal, because wet-lab work, clinical validation and data curation bring cost lines that a standard SaaS buyer may not expect.
Who they sell to
Buyers are typically clinical, scientific and operational rather than purely commercial. Heads of pathology, genomics, oncology, laboratory medicine, translational research, bioinformatics and clinical data often shape requirements, with procurement, information governance, finance and legal teams entering once a pilot looks usable. Pharmaceutical and research-organisation buyers may move through direct commercial discussions, while healthcare-provider work is more likely to involve formal procurement, validation committees and implementation planning. Initial contracts are often framed as feasibility studies, departmental deployments or service agreements before any wider roll-out, so sales cycles tend to run in months rather than weeks.
What they buy
Most precision medicine firms tend to spend on the operating layer around science and clinical delivery: laboratory information management systems, sample-tracking tools, bioinformatics workflow software, secure cloud infrastructure, data storage, analytics, quality management, information-governance support and cyber security. Commercial teams may also need CRM, proposal tooling, contract management and billing systems once they move beyond research partnerships into repeatable sales. Services spend often sits with regulatory advisers, clinical validation partners, specialist recruiters, grant and bid writers, accounting teams, legal counsel and marketing agencies able to explain technical evidence without over-claiming clinical utility.
Why and how to sell to them
Precision medicine buyers tend to evaluate vendors when evidence demands start to outrun internal capacity: a new clinical validation programme, a move from research use into regulated diagnostics, a laboratory expansion, a healthcare-provider pilot, or a larger pharmaceutical collaboration. Common pain points include slow procurement, fragmented clinical and research data, audit readiness, sample-chain visibility, security reviews and the cost of proving utility to cautious buyers. Outbound messages usually land better when they attach to a specific workflow burden, such as reducing validation administration, supporting MHRA or ICO-facing processes, improving lab throughput, or making customer evidence easier to package for procurement.
How this list is built
Data sources
This list is built from UK Companies House filings, XBRL accounts data, and semantic analysis of each company's public website. Revenue and headcount figures come from the most recent filed accounts; where the company has not filed, values are estimated using a model trained on filed history and peer benchmarks and are labelled as estimates.
Classification
Rather than relying solely on SIC codes, Firmbase classifies each company semantically: the company's website is crawled, an AI model reads what the company actually sells, and the company is placed into the relevant industry and subsectors. SIC codes are used as one signal but not the only one. This means a company that registered under a generic SIC code but pivoted into (for example) fintech is correctly identified as fintech, not as its original SIC category.
Freshness
The underlying company data is refreshed from Companies House continuously; filings appear in the list within days of submission. The curated list ordering is regenerated when the underlying data moves meaningfully (company count changes by more than 5%, a new company enters the top-ranked segment, or the filed-revenue numbers for the top firms change). You can see the last-updated timestamp near the top of the page.
Also in London
Related directories
Frequently asked questions
How many precision medicine companies are there in the London?↓
What counts as a precision medicine company in this list?↓
Which are the largest precision medicine companies in the London?↓
What do precision medicine companies in the London actually do?↓
How does London precision medicine compare internationally?↓
How is this list built and how fresh is the data?↓
How big are the typical precision medicine companies in the London?↓
Are these mostly new or established precision medicine companies?↓
What SIC codes does this use?↓
What buying signals should I look for?↓
Push these 42 companies into your pipeline.
Find the right decision-makers, see verified company data, and export your list in seconds.